Results 1 to 10 of about 300 (47)

A single-centre retrospective analysis of cinacalcet therapy in primary hyperparathyroidism

Endocrine Connections, 2021
Primary hyperparathyroidism (pHPT) is a common endocrine disorder that can be cured by parathyroidectomy; patients unsuitable for surgery can be treated with cinacalcet.
Daniel Bell, Julia Hale, Cara Go, Ben G Challis, Tilak Das, Brian Fish, Ruth T Casey   +6 more
doaj   +1 more source

Cinacalcet Targets the Neurokinin-1 Receptor and Inhibits PKCδ/ERK/P65 Signaling to Alleviate Dextran Sulfate Sodium-Induced Colitis

Frontiers in Pharmacology, 2021
Objective: Inflammatory bowel disease is an immune-mediated chronic inflammatory disease of the gastrointestinal tract for which curative drugs are currently not available.
Yuehong Chen, Huan Liu, Qiuping Zhang, Yubin Luo, Liang Wu, Yutong Zhong, Zhigang Tang, Yaoyu Pu, Chenyang Lu, Geng Yin, Qibing Xie   +10 more
doaj   +1 more source

Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World EffectivenessPlain-Language Summary

Kidney Medicine, 2022
Rationale & Objective: Some US hemodialysis (HD) facilities switched from oral cinacalcet to intravenous etelcalcetide as the primary calcimimetic therapy to control parathyroid hormone (PTH) levels after the introduction of etelcalcetide in 2017 ...
Angelo Karaboyas, Daniel Muenz, Yunji Hwang, William Goodman, Sunfa Cheng, Pooja Desai, Kathleen M. Fox, Bruce M. Robinson, Ronald L. Pisoni   +8 more
doaj   +1 more source

Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review

Frontiers in Endocrinology, 2023
IntroductionThis study aimed to systematically review research on cinacalcet and secondary hyperparathyroidism (SHPT) using machine learning-based statistical analyses.MethodsPublications indexed in the Web of Science Core Collection database on ...
Xiaosong Li, Wei Ding, Hong Zhang
doaj   +1 more source

Cinacalcet inhibition of neuronal action potentials preferentially targets the fast inactivated state of voltage-gated sodium channels

Frontiers in Physiology, 2022
Voltage-gated sodium channel (VGSC) activation is essential for action potential generation in the brain. Allosteric calcium-sensing receptor (CaSR) agonist, cinacalcet, strongly and ubiquitously inhibits VGSC currents in neocortical neurons via an ...
Jamie S. Lindner, Jamie S. Lindner, Salil R. Rajayer, Salil R. Rajayer, Briana J. Martiszus, Briana J. Martiszus, Stephen M. Smith, Stephen M. Smith   +7 more
doaj   +1 more source

A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. [PDF]

PLoS ONE, 2018
Cinacalcet hydrochloride (cinacalcet), an oral calcimimetic agent has been widely used for the management of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD).
Takehisa Kawata, Shin Tokunaga, Miki Murai, Nami Masuda, Waka Haruyama, Youji Shoukei, Yutaka Hisada, Tetsuya Yanagida, Hiroshi Miyazaki, Michihito Wada, Tadao Akizawa, Masafumi Fukagawa   +11 more
doaj   +1 more source

Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries

BMC Nephrology, 2019
Background The putative benefits of cinacalcet therapy for management of secondary hyperparathyroidism (SHPT) are thought to be most manifested when patients are taking it consistently and as prescribed. Real-world descriptions of cinacalcet prescription
Douglas S. Fuller, David Hallett, Paul J. Dluzniewski, Bruno Fouqueray, Michel Jadoul, Hal Morgenstern, Friedrich K. Port, Francesca Tentori, Ronald L. Pisoni   +8 more
doaj   +1 more source

Cinacalcet and primary hyperparathyroidism: systematic review and meta regression

Endocrine Connections, 2020
Purpose: Primary hyperparathyroidism (PHPT) is a common condition affect ing people of all ages and is mainly treated with parathyroidectomy. Cinacalcet has been widely used in secondary or tertiary hyperparathyroidism, but the use of cinacalcet in PHPT ...
Cheng Han Ng, Yip Han Chin, Marcus Hon Qin Tan, Jun Xuan Ng, Samantha Peiling Yang, Jolene Jiayu Kiew, Chin Meng Khoo   +6 more
doaj   +1 more source

Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease

Scientific Reports, 2021
A massively enlarged kidney can impact quality of life of autosomal dominant polycystic kidney disease (ADPKD) patients. A recent in vitro study demonstrated that an allosteric modulator of the calcium sensing receptor decreases adenosine-3′,5′-cyclic ...
Shinya Nakatani, Kozo Nishide, Senji Okuno, Eiji Ishimura, Daijiro Kabata, Fumiyuki Morioka, Yuri Machiba, Hideki Uedono, Akihiro Tsuda, Shigeichi Shoji, Masaaki Inaba, Katsuhito Mori, Tomoyuki Yamakawa, Masanori Emoto   +13 more
doaj   +1 more source

Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study. [PDF]

PLoS ONE, 2016
Anemia is an important prognostic factor in hemodialysis patients. It has been reported that parathyroidectomy ameliorates anemia and reduces the requirement of postoperative erythropoiesis-stimulating agents.
Motoko Tanaka, Kazuki Yoshida, Shingo Fukuma, Kazuko Ito, Kazutaka Matsushita, Masafumi Fukagawa, Shunichi Fukuhara, Tadao Akizawa   +7 more
doaj   +1 more source